Stock Analysis

Investors Don't See Light At End Of Cambridge Nutritional Sciences plc's (LON:CNSL) Tunnel

AIM:CNSL
Source: Shutterstock

You may think that with a price-to-sales (or "P/S") ratio of 0.9x Cambridge Nutritional Sciences plc (LON:CNSL) is definitely a stock worth checking out, seeing as almost half of all the Medical Equipment companies in the United Kingdom have P/S ratios greater than 3x and even P/S above 7x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.

See our latest analysis for Cambridge Nutritional Sciences

ps-multiple-vs-industry
AIM:CNSL Price to Sales Ratio vs Industry November 19th 2024

What Does Cambridge Nutritional Sciences' P/S Mean For Shareholders?

Cambridge Nutritional Sciences certainly has been doing a good job lately as it's been growing revenue more than most other companies. One possibility is that the P/S ratio is low because investors think this strong revenue performance might be less impressive moving forward. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.

Want the full picture on analyst estimates for the company? Then our free report on Cambridge Nutritional Sciences will help you uncover what's on the horizon.

What Are Revenue Growth Metrics Telling Us About The Low P/S?

The only time you'd be truly comfortable seeing a P/S as depressed as Cambridge Nutritional Sciences' is when the company's growth is on track to lag the industry decidedly.

Taking a look back first, we see that the company grew revenue by an impressive 30% last year. The latest three year period has also seen an excellent 43% overall rise in revenue, aided by its short-term performance. So we can start by confirming that the company has done a great job of growing revenue over that time.

Looking ahead now, revenue is anticipated to slump, contracting by 3.8% during the coming year according to the lone analyst following the company. With the industry predicted to deliver 140% growth, that's a disappointing outcome.

In light of this, it's understandable that Cambridge Nutritional Sciences' P/S would sit below the majority of other companies. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. Even just maintaining these prices could be difficult to achieve as the weak outlook is weighing down the shares.

What Does Cambridge Nutritional Sciences' P/S Mean For Investors?

It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.

As we suspected, our examination of Cambridge Nutritional Sciences' analyst forecasts revealed that its outlook for shrinking revenue is contributing to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

Before you settle on your opinion, we've discovered 2 warning signs for Cambridge Nutritional Sciences that you should be aware of.

If strong companies turning a profit tickle your fancy, then you'll want to check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About AIM:CNSL

Cambridge Nutritional Sciences

Develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market in the United Kingdom, rest of Europe, North America, South/Central America, India, rest of Asia and the Far East, Africa, and the Middle East.

Flawless balance sheet with questionable track record.